R&D News | pharmaphorum

News

Lilly aims for new indication for Taltz

Eli Lilly is hoping new data from its Taltz (ixekizumab) could give it another potentially lucrative indication and put pressure on Novartis’ rival IL-17a drug, Cosentyx.

News

Vertex's latest cystic fibrosis combination approved in US

Vertex’s quest to treat a wider group of patients with cystic fibrosis (CF) continues after the FDA approved its latest combination therapy, Symdeko.

News

Axovant CEO David Hung quits after Alzheimer's drug failure

Last month the biotech Axovant was rocked by the failure of its star drug intepirdine in Alzheimer’s disease – and the fall-out is still being felt, with CEO David Hung deciding to walk out.

News

Boehringer latest to axe Alzheimer's drug

Company will trial BI 409306 in schizophrenia instead.

News

J&J files next generation prostate cancer drug in Europe

After having filed its new prostate cancer drug apalutamide with the FDA in October, Johnson & Johnson have now submitted the drug to Europe’s EMA.

News

Belgium chosen for first J&J ‘JLABS’ incubator in Europe

Johnson & Johnson is rolling out its ‘no strings attached’ innovation incubator project JLABS to Europe – and has chosen a site in Belgium with a link to the company’s history.

Lilly aims for new indication for Taltz

Vertex's latest cystic fibrosis combination approved in US

Axovant CEO David Hung quits after Alzheimer's drug failure

Boehringer latest to axe Alzheimer's drug

J&J files next generation prostate cancer drug in Europe

Belgium chosen for first J&J ‘JLABS’ incubator in Europe

CHMP backs Novo's haemophilia A drug Frehemgo

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks